{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T13:43:20Z","timestamp":1782913400046,"version":"3.54.5"},"reference-count":67,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Tumor microenvironment influences the process of tumorigenesis, with hypoxia being a characteristic of many solid tumors and an adverse prognostic factor. Carbonic anhydrases (CAs) are highly efficient zinc-containing enzymes that are overexpressed in many cancers, particularly under acidic and hypoxic conditions. CA IX expression promotes cancer cell proliferation, migration, and invasion. Vascular endothelial growth factor receptor-2 (VEGFR-2) is a tyrosine transmembrane (\u03a4\u039c) protein regulating embryonic development, angiogenesis, tissue homeostasis and cancer. Blocking VEGFR-2 signaling is one of the most promising approaches to hindering angiogenesis and growth of cancer cells. The epidermal growth factor receptor (EGFR) is a member of the ERBB family of receptor tyrosine kinases and plays a key role in cancer progression. EGFR is uniquely found in some brain, lung and other cancers. Development of novel strategies to regulate these factors is important for the treatment of tumors. Multifunctional drugs that act on multiple pathways offer a promising approach, improving therapeutic effectiveness while reducing side effects. The present review focuses on novel compounds that inhibit CA IX and target VEGFR-2 or EGFR.<\/jats:p>","DOI":"10.3390\/molecules31132306","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T12:41:38Z","timestamp":1782909698000},"page":"2306","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dual Targeting Strategies in Cancer: Carbonic Anhydrase IX Inhibitors Targeting EGFR or VEGFR-2"],"prefix":"10.3390","volume":"31","author":[{"given":"Eleftherios","family":"Charissopoulos","sequence":"first","affiliation":[{"name":"Laboratory of Pharmaceutical Chemistry, School of Pharmacy, Faculty of Health Sciences, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0099-5653","authenticated-orcid":false,"given":"Eleni","family":"Pontiki","sequence":"additional","affiliation":[{"name":"Laboratory of Pharmaceutical Chemistry, School of Pharmacy, Faculty of Health Sciences, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/clinchem\/hvad202","article-title":"Epidemiology of Cancer","volume":"70","author":"Schwartz","year":"2024","journal-title":"Clin. Chem."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Cordani, M., Dando, I., Ambrosini, G., and Gonz\u00e1lez-Men\u00e9ndez, P. (2024). Signaling, cancer cell plasticity, and intratumor heterogeneity. Cell Commun. Signal., 22.","DOI":"10.1186\/s12964-024-01643-5"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"5512","DOI":"10.1002\/jcp.30276","article-title":"Signaling, metabolism, and cancer: An important relationship for therapeutic intervention","volume":"236","author":"Ferns","year":"2021","journal-title":"J. Cell. Physiol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Jiang, X., Wang, J., Deng, X., Xiong, F., Zhang, S., Gong, Z., Li, X., Cao, K., Deng, H., and He, Y. (2020). The role of microenvironment in tumor angiogenesis. J. Exp. Clin. Cancer Res., 39.","DOI":"10.1186\/s13046-020-01709-5"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1007\/s00018-019-03351-7","article-title":"Tumor angiogenesis: Causes, consequences, challenges and opportunities","volume":"77","author":"Lugano","year":"2020","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Morana, O., Wood, W., and Gregory, C.D. (2022). The Apoptosis Paradox in Cancer. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23031328"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.canlet.2020.12.020","article-title":"Metabolic adaptation in hypoxia and cancer","volume":"502","author":"Paredes","year":"2021","journal-title":"Cancer Lett."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Chen, Z., Han, F., Du, Y., Shi, H., and Zhou, W. (2023). Hypoxic microenvironment in cancer: Molecular mechanisms and therapeutic interventions. Signal Transduct. Target. Ther., 8.","DOI":"10.1038\/s41392-023-01332-8"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Buabeng, E.R., and Henary, M. (2021). Developments of small molecules as inhibitors for carbonic anhydrase isoforms. Bioorg. Med. Chem., 39.","DOI":"10.1016\/j.bmc.2021.116140"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"4421","DOI":"10.1021\/cr200176r","article-title":"Multiple Binding Modes of Inhibitors to Carbonic Anhydrases: How to Design Specific Drugs Targeting 15 Different Isoforms?","volume":"112","author":"Alterio","year":"2012","journal-title":"Chem. Rev."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.semcancer.2022.01.001","article-title":"Carbonic anhydrase IX: A tumor acidification switch in heterogeneity and chemokine regulation","volume":"86","author":"Queen","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Yang, H., Chen, R., Zheng, X., Luo, Y., Yao, M., Ke, F., Guo, X., Liu, X., and Liu, Q. (2025). Cooperative Role of Carbonic Anhydrase IX\/XII in Driving Tumor Invasion and Metastasis: A Novel Targeted Therapeutic Strategy. Cells, 14.","DOI":"10.3390\/cells14100693"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"123","DOI":"10.4149\/neo_2024_231219N652","article-title":"Can hypoxia marker carbonic anhydrase IX serve as a potential new diagnostic marker and therapeutic target of non-small cell lung cancer?","volume":"71","author":"Fecikova","year":"2024","journal-title":"Neoplasma"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"de Campos, N.S.P., Souza, B.S., da Silva, G.C.P., Porto, V.A., Chalbatani, G.M., Lagreca, G., Janji, B., and Suarez, E.R. (2022). Carbonic Anhydrase IX: A Renewed Target for Cancer Immunotherapy. Cancers, 14.","DOI":"10.3390\/cancers14061392"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Miura, K., and Nakamura, H. (2024). Development of carbonic anhydrase IX-targeting molecular-targeted photodynamic therapy. Bioorg. Med. Chem. Lett., 109.","DOI":"10.1016\/j.bmcl.2024.129821"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/s41416-019-0642-z","article-title":"Carbonic anhydrase IX and acid transport in cancer","volume":"122","author":"Becker","year":"2020","journal-title":"Br. J. Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1006\/geno.1996.0223","article-title":"Human MN\/CA9 Gene, a Novel Member of the Carbonic Anhydrase Family: Structure and Exon to Protein Domain Relationships","volume":"33","author":"Stanbridge","year":"1996","journal-title":"Genomics"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s13193-020-01076-9","article-title":"Role of CAIX Expression in Conventional Renal Cell Carcinomas as a Diagnostic Marker and its Prognostic Importance","volume":"12","author":"Ramachandran","year":"2021","journal-title":"Indian J. Surg. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Numprasit, W., Yangngam, S., Prasopsiri, J., Quinn, J.A., Edwards, J., and Thuwajit, C. (2023). Carbonic anhydrase IX-related tumoral hypoxia predicts worse prognosis in breast cancer: A systematic review and meta-analysis. Front. Med., 10.","DOI":"10.3389\/fmed.2023.1087270"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.3390\/molecules20022323","article-title":"Targeting Carbonic Anhydrase IX Activity and Expression","volume":"20","author":"Mahon","year":"2015","journal-title":"Molecules"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Ronca, R., and Supuran, C.T. (2024). Carbonic anhydrase IX: An atypical target for innovative therapies in cancer. Biochim. Biophys. Acta Rev. Cancer, 1879.","DOI":"10.1016\/j.bbcan.2024.189120"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1158\/0008-5472.CAN-08-2470","article-title":"Hypoxia-Inducible Carbonic Anhydrase IX and XII Promote Tumor Cell Growth by Counteracting Acidosis through the Regulation of the Intracellular pH","volume":"69","author":"Chiche","year":"2009","journal-title":"Cancer Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"20473","DOI":"10.1074\/jbc.M801330200","article-title":"Tumor-associated Carbonic Anhydrase 9 Spatially Coordinates Intracellular pH in Three-dimensional Multicellular Growths","volume":"283","author":"Swietach","year":"2008","journal-title":"J. Biol. Chem."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.4155\/fmc.15.71","article-title":"Carbonic Anhydrase Ix Inhibitors in Cancer Therapy: An Update","volume":"7","author":"Supuran","year":"2015","journal-title":"Future Med. Chem."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Denner, T.C., Angeli, A., Ferraroni, M., Supuran, C.T., and Csuk, R. (2023). Ureidobenzenesulfonamides as Selective Carbonic Anhydrase I, IX, and XII Inhibitors. Molecules, 28.","DOI":"10.3390\/molecules28237782"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3828","DOI":"10.1016\/j.bmcl.2005.06.055","article-title":"Carbonic anhydrase inhibitors: Inhibition of the transmembrane isozyme XIV with sulfonamides","volume":"15","author":"Nishimori","year":"2005","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/S0960-894X(03)00091-X","article-title":"Carbonic anhydrase inhibitors: Inhibition of the tumor-associated isozyme IX with aromatic and heterocyclic sulfonamides","volume":"13","author":"Vullo","year":"2003","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1016\/j.bmc.2017.03.027","article-title":"Synthesis and carbonic anhydrase inhibition of a series of SLC-0111 analogs","volume":"25","author":"Carta","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"815","DOI":"10.2174\/1568026620666200303123102","article-title":"Review on Epidermal Growth Factor Receptor (EGFR) Structure, Signaling Pathways, Interactions, and Recent Updates of EGFR Inhibitors","volume":"20","author":"Sabbah","year":"2020","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Yadav, T.T., Shaikh, G.M., Kumar, M.S., Chintamaneni, M., and Mohanty, Y.C. (2022). A Review on Fused Pyrimidine Systems as EGFR Inhibitors and Their Structure\u2013Activity Relationship. Front. Chem., 10.","DOI":"10.3389\/fchem.2022.861288"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1002\/ddr.21925","article-title":"An appraisal of anticancer activity with structure\u2013activity relationship of quinazoline and quinazolinone analogues through EGFR and VEGFR inhibition: A review","volume":"83","author":"Haider","year":"2022","journal-title":"Drug Dev. Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.semcancer.2022.04.002","article-title":"EGFR signaling pathway as therapeutic target in human cancers","volume":"85","author":"Levantini","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.critrevonc.2019.09.001","article-title":"Targeting EGFR pathway in metastatic colorectal cancer-tumour heterogeniety and convergent evolution","volume":"143","author":"Khan","year":"2019","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Alharbi, K.S., Shaikh, M.A.J., Afzal, O., Altamimi, A.S.A., Almalki, W.H., Alzarea, S.I., Kazmi, I., Al-Abbasi, F.A., Singh, S.K., and Dua, K. (2022). An overview of epithelial growth factor receptor (EGFR) inhibitors in cancer therapy. Chem. Biol. Interact., 366.","DOI":"10.1016\/j.cbi.2022.110108"},{"key":"ref_35","first-page":"67","article-title":"Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations-a review","volume":"4","author":"Stewart","year":"2015","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.jtho.2024.03.016","article-title":"Unveiling the Landscape of Uncommon EGFR Mutations in NSCLC-A Systematic Review","volume":"19","author":"Borgeaud","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"19","DOI":"10.4062\/biomolther.2021.047","article-title":"Chronicles of EGFR Tyrosine Kinase Inhibitors: Targeting EGFR C797S Containing Triple Mutations","volume":"30","author":"Duggirala","year":"2022","journal-title":"Biomol. Ther."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"731","DOI":"10.2174\/1871520611313050008","article-title":"Type II Kinase Inhibitors: An Opportunity in Cancer for Rational Design","volume":"13","author":"Blanc","year":"2013","journal-title":"Anticancer Agents Med. Chem."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Mabeta, P., and Steenkamp, V. (2022). The VEGF\/VEGFR Axis Revisited: Implications for Cancer Therapy. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232415585"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Aziz, M.A., Serya, R.A.T., Lasheen, D.S., Abdel-Aziz, A.K., Esmat, A., Mansour, A.M., Singab, A.N.B., and Abouzid, K.A.M. (2016). Discovery of Potent VEGFR-2 Inhibitors based on Furopyrimidine and Thienopyrimidne Scaffolds as Cancer Targeting Agents. Sci. Rep., 6.","DOI":"10.1038\/srep24460"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Liu, X.-J., Zhao, H.-C., Hou, S.-J., Zhang, H.-J., Cheng, L., Yuan, S., Zhang, L.-R., Song, J., Zhang, S.-Y., and Chen, S.-W. (2023). Recent development of multi-target VEGFR-2 inhibitors for the cancer therapy. Bioorg. Chem., 133.","DOI":"10.1016\/j.bioorg.2023.106425"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Ghalehbandi, S., Yuzugulen, J., Pranjol, M.Z.I., and Pourgholami, M.H. (2023). The role of VEGF in cancer-induced angiogenesis and research progress of drugs targeting VEGF. Eur. J. Pharmacol., 949.","DOI":"10.1016\/j.ejphar.2023.175586"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Charissopoulos, E., and Pontiki, E. (2025). Sulfonamides a Promising Hit for Cancer Therapy Through VEGFR-2 Inhibition. Biomedicines, 13.","DOI":"10.3390\/biomedicines13040772"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Zhu, X., and Zhou, W. (2015). The Emerging Regulation of VEGFR-2 in Triple-Negative Breast Cancer. Front. Endocrinol., 6.","DOI":"10.3389\/fendo.2015.00159"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.ejso.2013.08.032","article-title":"The role of VEGFR-2 expression in outcomes and survival of patients with peritoneal carcinomatosis from appendiceal cancer","volume":"39","author":"Jimenez","year":"2013","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.mam.2011.04.004","article-title":"Vascular endothelial growth factors and receptors: Anti-angiogenic therapy in the treatment of cancer","volume":"32","author":"Tugues","year":"2011","journal-title":"Mol. Asp. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1517\/14656566.2010.496453","article-title":"Sorafenib: A clinical and pharmacologic review","volume":"11","author":"Iyer","year":"2010","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1634\/theoncologist.2012-0044","article-title":"FDA Approval Summary: Sunitinib for the Treatment of Progressive Well-Differentiated Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors","volume":"17","author":"Blumenthal","year":"2012","journal-title":"Oncologist"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/978-3-319-91442-8_3","article-title":"Regorafenib","volume":"211","author":"Ettrich","year":"2018","journal-title":"Recent Results Cancer Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e484","DOI":"10.1002\/onco.13566","article-title":"FDA Supplemental Approval Summary: Lenvatinib for the Treatment of Unresectable Hepatocellular Carcinoma","volume":"26","author":"Nair","year":"2021","journal-title":"Oncologist"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1158\/1078-0432.CCR-24-0281","article-title":"FDA Approval Summary: Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer","volume":"30","author":"Fusco","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Zeidan, M.A., Al-Sanea, M.M., Elnagar, M.R., Tawfik, M.M., El-Shafey, H.W., Tawfik, S.S., Brogi, S., and Hamdi, A. (2026). Quinazoline-sulfonamide hybrids as multitarget anticancer agents: Inhibition of carbonic anhydrase IX\/XII isoforms and VEGFR-2 with in vitro and in silico validation. Mol. Divers., advance online publication.","DOI":"10.1007\/s11030-026-11543-0"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1039\/D5MD01043H","article-title":"Discovery of enaminone-linked benzofuran derivatives as dual VEGFR-2\/hCA IX inhibitors exhibiting hypoxia-mediated chemosensitization","volume":"17","author":"Eldehna","year":"2026","journal-title":"RSC Med. Chem."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"El-Attar, M.A.Z., Afifi, O.S., Ismail, A., Kamel, Y.N., Yassin, H.A., Nomeir, H.M., Nematalla, H.A., Angeli, A., Labib, H.F., and Eldehna, W.M. (2026). Click-modifiable isatin hydrazones as COX-2, VEGFR-2, and carbonic anhydrase inhibitors: A multi-target approach to cancer therapy. Eur. J. Med. Chem., 302.","DOI":"10.1016\/j.ejmech.2025.118304"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Zengin, M., Unsal Tan, O., Sabuncuoglu, S., Arafa, R.K., and Balkan, A. (2024). Design and Discovery of New Dual Carbonic Anhydrase IX and VEGFR-2 Inhibitors Based on the Benzenesulfonamide-Bearing 4-Thiazolidinones\/2,4-Thiazolidinediones Scaffold. Drug Dev. Res., 85.","DOI":"10.1002\/ddr.70030"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"7406","DOI":"10.1021\/acs.jmedchem.4c00239","article-title":"Discovery and Mechanistic Studies of Dual-Target Hits for Carbonic Anhydrase IX and VEGFR-2 as Potential Agents for Solid Tumors: X-ray, In Vitro, In Vivo, and In Silico Investigations of Coumarin-Based Thiazoles","volume":"67","author":"Hefny","year":"2024","journal-title":"J. Med. Chem."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Abbas, H.A.S., Nossier, E.S., El-Manawaty, M.A., and El-Bayaa, M.N. (2024). New sulfonamide-based glycosides incorporated 1,2,3-triazole as cytotoxic agents through VEGFR-2 and carbonic anhydrase inhibitory activity. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-62864-9"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"10558","DOI":"10.1021\/acs.jmedchem.3c00721","article-title":"1,5-Diaryl-1,2,4-triazole Ureas as New SLC-0111 Analogues Endowed with Dual Carbonic Anhydrase and VEGFR-2 Inhibitory Activities","volume":"66","author":"Elsawi","year":"2023","journal-title":"J. Med. Chem."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Saied, S., Shaldam, M., Elbadawi, M.M., Giovannuzzi, S., Nocentini, A., Almahli, H., Salem, R., Ibrahim, T.M., Supuran, C.T., and Eldehna, W.M. (2023). Discovery of indolinone-bearing benzenesulfonamides as new dual carbonic anhydrase and VEGFR-2 inhibitors possessing anticancer and pro-apoptotic properties. Eur. J. Med. Chem., 259.","DOI":"10.1016\/j.ejmech.2023.115707"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Shaldam, M.A., Almahli, H., Angeli, A., Badi, R.M., Khaleel, E.F., Zain-Alabdeen, A.I., Elsayed, Z.M., Elkaeed, E.B., Salem, R., and Supuran, C.T. (2023). Discovery of sulfonamide-tethered isatin derivatives as novel anticancer agents and VEGFR-2 inhibitors. J. Enzym. Inhib. Med. Chem., 38.","DOI":"10.1080\/14756366.2023.2203389"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1142\/S2737416526500225","article-title":"Design, Computational, Synthesis, and Anti-Cancer Evaluation of a Multifunctional 2,3-Dihydro-1,3,4-Thiadiazole-Benzenesulfonamide Hybrid as a Triple Inhibitor of CAIX, CAXII, and EGFR","volume":"25","author":"Eissa","year":"2026","journal-title":"J. Comput. Biophys. Chem."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1080\/17568919.2025.2498879","article-title":"Development of new anticancer thiadiazole-sulfonamides as dual EGFR\/carbonic anhydrase inhibitors","volume":"17","author":"Eissa","year":"2025","journal-title":"Future Med. Chem."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Eissa, I.H., Elkady, H., Elgammal, W.E., Mahdy, H.A., Husein, D.Z., Amin, F.G., Elsheshiny, A.A.A., Abdelfattah, S.S., Alsfouk, A.A., and Elkaeed, E.B. (2025). A novel sulfamoylphenyl-dihydro-thiadiazole derivative as a dual EGFR and carbonic anhydrase inhibitor for cancer therapy. PLoS ONE, 20.","DOI":"10.1371\/journal.pone.0328305"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Elkaeed, E.B., Elkady, H., Elgammal, W.E., Mahdy, H.A., Husein, D.Z., Ibrahim, I.M., Al-ghulikah, H.A., Eissa, I.H., and Metwaly, A.M. (2025). A novel thiadiazole-based dual inhibitor of carbonic anhydrase-IX and epidermal growth factor receptor targeting cancer: A combined in silico and in vitro approach. J. Chem. Res., 49.","DOI":"10.1177\/17475198251400403"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Eldehna, W.M., Elsayed, Z.M., Ammara, A., El Hassab, M.A., Almahli, H., Fares, M., Nocentini, A., Supuran, C.T., and Abou-Seri, S.M. (2024). Discovery of new sulfonamide-tethered 2-aryl-4-anilinoquinazolines as the first-in-class dual carbonic anhydrase and EGFR inhibitors. Int. J. Biol. Macromol., 279.","DOI":"10.1016\/j.ijbiomac.2024.135010"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Shaldam, M.A., Khalil, A.F., Almahli, H., Jaballah, M.Y., Angeli, A., Khaleel, E.F., Badi, R.M., Elkaeed, E.B., Supuran, C.T., and Eldehna, W.M. (2024). Identification of 3-(5-cyano-6-oxo-pyridin-2-yl)benzenesulfonamides as novel anticancer agents endowed with EGFR inhibitory activity. Arch. Pharm., 357.","DOI":"10.1002\/ardp.202300449"},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Zhang, B., Liu, Z., Xia, S., Liu, Q., and Gou, S. (2021). Design, synthesis and biological evaluation of sulfamoylphenyl-quinazoline derivatives as potential EGFR\/CAIX dual inhibitors. Eur. J. Med. Chem., 216.","DOI":"10.1016\/j.ejmech.2021.113300"}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/31\/13\/2306\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T12:43:22Z","timestamp":1782909802000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/31\/13\/2306"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":67,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["molecules31132306"],"URL":"https:\/\/doi.org\/10.3390\/molecules31132306","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]}}}